Zoe Eloise Quandt
Endocrinology · San Francisco
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 5
Offices
5 locations · UCSF Medical Group Business Services · Regents of the University of California · University of California San Francisco
Hospitals listed: UCSF Medical Center. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Zoe Eloise Quandt’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A131799 · Current
Licensed to practise in California · since 2014 · expires 2028-01-31 · University of California San Francisco School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- UCSF Medical CenterSan Francisco, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of University of California Health, which runs 12 hospitalsHome of UCSF Helen Diller Family Comprehensive Cancer Center, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 81% would definitely recommend itOverall rating: 4 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 4.9 (3.79 to 6.02) · 7,590 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 12.8 (11.3 to 14.4) · 2,019 cases, Jan 2024 – Dec 2024Better than the national rate — Death rate among surgical inpatients with serious treatable complications: 139.4 (110.22 to 168.58) · 452 cases, Jul 2022 – Jun 2024Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.622, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.626, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.491, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.8 (0.7 to 1) · 2,336 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for UCSF Medical Center
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 3 better, 5 the same, 3 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.9 (3.79 to 6.02) · 7,590 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.8 (11.3 to 14.4) · 2,019 cases | Worse | Jan 2024 – Dec 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 139.4 (110.22 to 168.58) · 452 cases | Better | Jul 2022 – Jun 2024 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.622 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.626 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.491 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.8 (0.7 to 1) · 2,336 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.24 (0.58 to 1.9) · 4,689 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.05 (0.89 to 1.2) | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.5 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.1 · 132 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.6 · 454 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 618 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.6 · 380 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.7 · 5,000 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.22 (0.06 to 0.38) · 15,965 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.05 to 0.35) · 17,859 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.85 (0 to 1.83) · 4,184 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2 (1.1 to 2.9) · 6,516 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.35 (4.49 to 10.21) · 3,989 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5 (3.22 to 6.77) · 4,087 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.95 (0.74 to 3.15) · 2,034 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.95 (0.63 to 1.28) · 15,431 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 399 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.899 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.689 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.224 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16 · 156 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20 · 564 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 60.3 · 160 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -9.7 · 550 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 44.1 · 660 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.8 · 667 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (4.8 to 6.7) · 2,019 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6 · 421 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20 · 107 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.9 (11.3 to 17.1) · 3,247 cases | No different | Jan 2022 – Dec 2024 |
What patients said (3,181 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 71% |
| Nurses "always" communicated well | 80% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 61% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 75% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 50% |
| "YES", patients would definitely recommend the hospital | 81% |
| Staff "always" explained possible side effects | 46% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$19,528
Medicare paid this office $19,528 for 87 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 50 | $6,779 | $82 |
| Long return visit (40+ min) | 23 | $4,325 | $120 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 17 | $1,961 | $115 |
Who their Medicare patients are
87 Original Medicare patients in 2024. Average age 70 · Women 39% · Also on Medicaid 26% · Health risk score 3.14. Sicker patients than 9 in 10 peers; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 71% · Diabetes 51% · Chronic kidney disease 41% · Coronary heart disease 40% · Cancer 36% · Heart failure 32% · Atrial fibrillation 31% · Depression 21% · COPD 18% · Stroke 13%.
The office billed $134,533, Medicare allowed $25,519 and paid $19,528; for 326 services of 19 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 87 | 326 | 70 | 3.14 | $134,533 | $19,528 |
| 2023 | 78 | 311 | 70 | 2.20 | $134,092 | $18,996 |
| 2022 | 65 | 242 | 69 | 2.21 | $127,069 | $20,998 |
| 2021 | 53 | 103 | 68 | 2.65 | $70,838 | $11,019 |
| 2020 | 54 | 141 | 67 | 1.92 | $86,354 | $11,355 |
| 2019 | 27 | 57 | 70 | 1.89 | $42,403 | $4,912 |
| 2018 | 20 | 25 | 68 | 1.03 | $21,385 | $2,758 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 2 services
| Return visit (30+ min) | 44 | $5,989 | $83 |
| Long return visit (40+ min) | 35 | $5,708 | $114 |
2022: 2 services
| Long return visit (40+ min) | 39 | $9,013 | $125 |
| Return visit (30+ min) | 47 | $5,879 | $79 |
2021: 2 services
| Long return visit (40+ min) | 35 | $6,942 | $122 |
| Return visit (30+ min) | 15 | $1,349 | $79 |
2020: 2 services
| Long return visit (40+ min) | 30 | $5,442 | $99 |
| Return visit (30+ min) | 23 | $2,915 | $66 |
2019: 2 services
| Return visit (30+ min) | 17 | $1,635 | $63 |
| New patient visit (60+ min) | 12 | $1,427 | $119 |
2018: 1 service
| New patient visit (60+ min) | 11 | $1,639 | $149 |
Medicaid work
$1,457 in 2023
Medicaid paid $1,457 for 13 billed services this clinician did in 2023, up to 13 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| IP/OBS CONSLTJ NEW/EST PT MOD MDM 60 MINUTES | 13 | $1,457 |
| 2023 | 13 | 1 | 13 | $1,457 |
Drugs they prescribed that Part D paid
$87,842
Pharmacies billed $87,842 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 367) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
174 generic and 170 brand-name prescriptions · $87,842 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Testosterone | 31 | $6,266 | $202 |
| Tradjenta | 12 | $6,174 | $515 |
| Hydrocortisone | 55 | $3,590 | $65 |
| Nano 2nd Gen Pen Needle | 15 | $1,216 | $81 |
| Levothyroxine | 76 | $1,099 | $14 |
See all 7 drugs
| Testosterone | 31 | $6,266 | $202 |
| Tradjenta | 12 | $6,174 | $515 |
| Hydrocortisone | 55 | $3,590 | $65 |
| Nano 2nd Gen Pen Needle | 15 | $1,216 | $81 |
| Levothyroxine | 76 | $1,099 | $14 |
| Cabergoline | 12 | $756 | $63 |
| Humalog | 11 | $739 | $67 |
Year by year
| 2024 | 367 | 55 | 0% (0) | 46% | $87,842 |
| 2023 | 260 | 47 | 0% (0) | 41% | $66,921 |
| 2022 | 298 | 50 | 0% (0) | 42% | $60,082 |
| 2021 | 253 | 48 | 0% (0) | None | $71,302 |
| 2020 | 136 | 35 | 0% (0) | 54% | $37,714 |
| 2019 | 83 | 20 | 0% (0) | 72% | $12,903 |
| 2018 | 75 | 19 | 0% (0) | None | $5,206 |
| 2017 | 50 | 15 | 0% (0) | 48% | $6,383 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Testosterone | 19 | $7,213 | $380 |
| Hydrocortisone | 67 | $4,622 | $69 |
| Levothyroxine | 54 | $1,141 | $21 |
| Metformin Hcl Er | 14 | $399 | $29 |
2022: 6 drugs
| Testosterone | 19 | $4,580 | $241 |
| Hydrocortisone | 54 | $3,035 | $56 |
| Levothyroxine | 83 | $1,494 | $18 |
| Cabergoline | 13 | $794 | $61 |
| Prednisone | 11 | $302 | $27 |
| Metformin Hcl Er | 21 | $270 | $13 |
2021: 4 drugs
| Testosterone | 24 | $5,133 | $214 |
| Hydrocortisone | 61 | $4,677 | $77 |
| Levothyroxine | 52 | $1,280 | $25 |
| Cabergoline | 20 | $1,156 | $58 |
2020: 2 drugs
| Hydrocortisone | 26 | $1,333 | $51 |
| Levothyroxine | 31 | $896 | $29 |
2019: 2 drugs
| Hydrocortisone | 24 | $677 | $28 |
| Levothyroxine | 28 | $492 | $18 |
2018: 1 drug
| Levothyroxine | 26 | $655 | $25 |
2017: 1 drug
| Levothyroxine | 18 | $432 | $24 |
Money from drug and device companies
$6,218 in 2025
| 2025 | 2 | 7 | $5,687 | $6,218 |
| 2024 | 1 | 5 | None | $958 |
| 2023 | 1 | 4 | $6,088 | $6,319 |
| 2022 | 1 | 6 | $8,289 | $8,289 |
| 2019 | 1 | 1 | None | $35 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sanofi-Aventis U.S. | Tzield | $3,175 | 4 payments
|
| Genzyme | Tzield | $3,043 | 3 payments
|
See all 7 published payments
| Sanofi-Aventis U.S. | Meals · 2025-10-14 | None | $144 |
| Sanofi-Aventis U.S. | Consulting · 2025-10-14 | None | $2,712 |
| Sanofi-Aventis U.S. | Meals · 2025-07-13 | Tzield | $170 |
| Sanofi-Aventis U.S. | Paid to speak or teach · 2025-06-21 | None | $150 |
| Genzyme | Meals · 2025-05-01 | Tzield | $198 |
| Genzyme | Consulting · 2025-05-01 | Tzield | $2,825 |
| Genzyme | Travel · 2025-05-01 | Tzield | $20 |
See earlier years (2024, 2023, 2022, 2019)
2024: $958
| Sanofi-Aventis U.S. | Tzield | $958 | 5 payments
|
2023: $6,319
| Sanofi-Aventis U.S. | Tzield | $6,319 | 4 payments
|
2022: $8,289
| Novartis Pharmaceuticals | Piqray | $8,289 | 6 payments
|
2019: $35
| Medtronic MiniMed | Minimed 670g System | $35 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novartis Pharmaceuticals Corporation · Expert Consensus Recommendations for Managing Hyperglycemia and Rash Associated With Alpelisib-Breast Cancer Res Treat · 2023 | This clinician | $6,154 |
| NOVARTIS PHARMACEUTICALS CORPORATION · Publication Support Provided in Connection With Heor Research · 2022 | This clinician | $619 |
| Novartis Pharmaceuticals Corporation · Byl-Ab -117225-Expert Consensus Recommendations for Managing Hyperglycemia and Rash in Patients With Pik3ca-Mutated, Hormone Receptor-Positive (Hr+), Human Epidermal Growth Factor Receptor 2-Negative (Her2?) Advanced Breast Cancer (Abc) Treated With Alp · 2023 | This clinician | $396 |
| F. Hoffmann-La Roche AG · Polygenic Risk Score Associations With Immune Checkpoint Inhibitors Related Endocrine Toxicity · 2024 | This clinician | $176 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1861735714
- Licence
- CA A131799California A131799: Current · expires 2028-01-31
- Group
- UCSF Medical Group Business Services · Regents of the University of California · University of California San Francisco
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Internal medicine (207R00000X); Student in a training program (390200000X)
- Mailing address
- 400 Parnassus Ave. Ste 550, San Francisco, CA, 94143
- NPI first listed
- 2013-03-28
- NPI last updated
- 2019-07-09
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 300 Pasteur Dr, Stanford, CA, 94305